Abstract: The present invention provides a resist composition containing a base resin composed of a polymer compound having a repeating unit in which a hydrogen atom of a carboxyl group is substituted with one or more acid-labile groups selected from groups shown by the following general formulae (1-1) to (1-5), wherein R1 to R5 represent a linear, branched, or cyclic alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, or an alkynyl group having 2 to 4 carbon atoms; R6 represents a hydroxyl group or an alkoxy group or acyloxy group having 1 to 6 carbon atoms; and “m” represents 1 or 2. There can be provided a resist composition that can improve the dissolution contrast of a resist film and reduce the film shrinkage after PEB, and a patterning process using the same.

Abstract: A method of producing ?1,4-Tibolone (C21H26O2), 10?-Hydroxy-?4-tibolone (C21H28O3). 11?,15?-Dihydroxytibolone (C21H28O4) and 11?,15?-Dihydroxy-?5-tibolone (C21H28O4) by contacting tibolone and 3?,6?-Dihydroxytibolone (C21H32O3) by contacting 3?-hydroxytibolone with Cunninghamella elegans (ATCC 10028b) is reported.

Abstract: A novel method of synthesis for the manufacture of upstream products for the production of compounds with general formulas 8, 10, and 12 is described. In this synthesis, compounds with general formula 4,B are produced in a microbiological reaction.

Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.

Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.

Abstract: The present invention relates to a novel cytochrome P450-like enzyme (Aspergillus ochraceus 11 alpha hydroxylase) and an oxidoreductase (Aspergillus ochraceus oxidoreductase) isolated from cDNA library generated from the mRNA of Aspergillus ochraceus spores. When the cDNA encoding the 11 alpha hydroxylase was co-expressed in Spodoptera frugiperda (Sf-9) insect cells with the cDNA encoding human oxidoreductase as an electron donor, it successfully catalyzed the conversion of the steroid substrate 4-androstene-3,17-dione (AD) to 11 alpha-hydroxy-AD as determined by HPLC analysis. The invention also relates to nucleic acid molecules associated with or derived from these cDNAs including complements, homologues and fragments thereof, and methods of using these nucleic acid molecules, to generate, for example, polypeptides and fragments thereof. The invention also relates to the generation of antibodies that recognizes the A.

Abstract: The invention relates to a microbial method of in vitro transformation of a steroid into its corresponding 11.alpha.-hydroxy analogue using oxygen and a microorganism selected from the Aspergillus ochraceus, Aspergillus niger, Rhizopus stolonifer, Rhizopus nigricans, Rhizopus arrhizus, and strains of Pestelotia, using as substrate a steroid having a purity of less than 97% and more than 90% at a concentration greater than 10 g/l.

Abstract: The present invention provides nucleic acid sequences for T-cell receptors which recognize tumor associated antigens. In particular, T-cell receptors which recognize melanoma antigens. This invention also provides T-cells expressing the antigen specific T-cell receptors. In addition, this invention provides stem cells expressing the antigen specific T-cell receptors or chimeric receptors. This invention further relates to therapeutic and diagnostic compositions and methods employing the T-cell receptors and chimeric receptors provided herein.

Abstract: A method to produce novel polyketide structures by designing and introducing specified changes in the DNA governing the synthesis of the polyketide is disclosed. The biosynthesis of specific polyketide analogs is accomplished by genetic manipulation of a polyketide-producing microorganism by isolating a polyketide biosynthetic gene-containing DNA sequence, identifying enzymatic activities associated within the DNA sequence, introducing one or more specified changes into the DNA sequence which codes for one of the enzymatic activities which results in an altered DNA sequence, introducing the altered DNA sequence into the polyketide-producing microorganism to replace the original sequence, growing a culture of the altered microorganism under conditions suitable for the formation of the specific polyketide analog, and isolating the specific polyketide analog from the culture.

Abstract: Nucleic acids segment comprising a nucleotide coding sequence for Pseudomonas testosteroni .DELTA.1-dehydrogenase or an homologous or complementary nucleotide sequences thereof.

Abstract: Provided are stable hydrate crystals of 14.alpha.-hydroxy-4-androstene-3,6,17-trione having a biological activity of human placenta-originating estrodiene synthesis enzyme inhibitory action. These hydrate crystals include two kinds of 14.alpha.-hydroxy-4-androstene-3,6,17-trione hydrate crystals having a diffraction pattern having characteristic peaks at diffraction angles in crystalline powder X-ray diffraction. Processes for producing these hydrate crystals are also provided.

Abstract: L-tryptophan is produced by constructing a recombinant DNA composed of a vector DNA and DNA fragments bearing all of genetic information relating to the synthesis of DS, AS, PRT, PRAI, InGPS and TS, introducing the recombinant DNA in a microorganism belonging to the genus Corynebacterium or Brevibacterium, culturing the microorganism in a medium, and recovering L-tryptophan accumulated in the culture.

Abstract: The present invention is concerned with a novel biotransformation process for producing 17.beta.-N-monosubstituted carbamoyl-11-oxo-4-aza-5-.alpha.-androst-3-ones of the formula: ##STR1## These compounds are testosterone 5-.alpha. reductase inhibitors and are produced via a claimed novel biotransformation process using the green algae, Selenastrum capricornutum.

Abstract: Novel androst-4-ene-3,17-dione derivatives are disclosed. The group of these compounds has biological activities, in particular, the inhibiting activity on human placenta-derived estrogen-synthesizing enzyme. Therefore these compounds are expected to be utilized in the field of medical care, particularly as anticancer drugs.

Abstract: The practice of this invention provides a photosensitive member which comprises a charge generating layer, and a plasma-polymerized layer, wherein said plasma-polymerized layer having an infrared absorption spectrum of a ratio of coefficients of absorptivities attributed to methyl group (--CH.sub.3) to those of methylene group (--CH.sub.2 --), and is a coefficient of absorptivity attributed to methylene group (--CH.sub.2 --) at about 2925 cm.sup.-1. The photosensitive member obtained thereby is excellent in charge-transporting property and chargeability and, moreover, exhibits advantages in corona resistance and resistances to acids, moisture and heat and also in physical properties such as stiffness.

Abstract: Disclosed is a complete description of the preparation of novel, substantially pure polypeptide via recombinant DNA techniques utilizing any of an assortment of expression vectors and host cultures. The polypeptide, human immune (gamma) interferon (IFN-.gamma.), is isolated and characterized in terms of DNA and amino acid sequences, physical attributes and biological activity.

Abstract: A polycistronic construction of xenogeneic sequences expressible in eukaryotic cells is described. DHFR encoding sequences under control of the same promoter with another foreign gene can be amplified with methotrexate, and thus cause coamplification of the foreign gene.

Abstract: Recombinant vector plasmids containing a DNA fragment coding for human interferon-.beta. inserted downstream from a tryptophan promoter are useful for transformation of microorganisms such as Escherichia coli which transformants produce human interferon-.beta..

Abstract: A biocatalyst contains microorganisms, e.g., of the species Arthrobacter simplex, Aspergillus ochraceus, Bacillus sphaericus, Curvularia lunata, Flavobacterium dehydrogenans, Mycobacterium spec., or Saccharaomyces uvarum, immobilized on a copolymer of acrolein and 1-vinyl-2-pyrrolidone, crosslinked by reaction with an alkylenedioxydiamine of the formulaH.sub.2 NO--(CH.sub.2).sub.n ONH.sub.2wherein n is a number of 2 to 12. The preparation of steroids is also disclosed.

Abstract: Microbiological conversions of cyclodextrins are intensified by adding to the reaction mixture 0.2 to 3 moles of .alpha.-, .beta.- or .gamma.-cyclodextrin or an optical mixture thereof pro mole of the steroid substrate, before, at the beginning or during the conversion. The cyclodextrin if desired, can be removed after the reaction. In this way the reaction velocity can be increased, the reaction time is reduced, the substrate concentration in the solution, i.e. its solubility is increased or the so called product inhibition may be avoided. In certain cases of more alternatives the desired reaction can be catalyzed and in this manner the selectivity is increased.

Abstract: A method for activating immobilized living microorganisms applied to transformations of steroids, antibiotics and other compounds characterized by the addition of peptone, glucose or a mixture of peptone and glucose to the reaction mixture.

Abstract: A water-soluble hydrolyzate of elastin, suitable for cosmetological use, is disclosed as is a method for making a water-soluble elastin hydrolyzate from starting materials containing elastin which comprises first subjecting said starting material to acid treatment at a pH below about 4 and at an elevated temperature and then enzymatically degrading the acid-treated material, while in comminuted form, in an aqueous bath in the presence of urea, with an alkaline proteinase having an activity optimum in a range between pH 9 and pH 13, the initial pH of the enzymatic treatment being within the pH range optimum for the enzyme employed.